Azafaros is focussed on the treatment of rare metabolic disorders.
The company aims at developing therapeutic agents for the treatment of rare metabolic disorders
such as lysosomal storage disorders through oral administration of azasugar compounds. These
novel, very promising agents were discovered by Professor Hans Aerts and Professor Hermen
Overkleeft at Amsterdam UMC and Leiden University, and are exclusively licensed to Azafaros.
Rare metabolic disordersRare metabolic disorders such as lysosomal storage disorders (LSDs) represent a broad class of severe and sometimes life-threatening inherited diseases, presenting significant unmet medical needs, with only few approved therapies.
With its proprietary small molecule compounds, Azafaros will concentrate on new treatments for patients suffering from LSDs and LSD-related diseases. These compounds interfere with the metabolism of glycolipids that is disturbed in these patients and are intended to counteract the underlying pathological effects.
LeadershipOlivier Morand, Ph.D. and IMD alumnus, is joining Azafaros as Chief Executive Officer (CEO) and member of the Board of Directors. Olivier, a senior leader in pharma strategic development for early- and late-phase products, brings many years of hand-on experience and know-how in rare metabolic disorders and orphan drugs.
Olivier has a very strong industry track record most recently at Idorsia Pharmaceuticals, and before that at Actelion Pharmaceuticals and Hoffmann-La Roche. Olivier brings a broad scientific, clinical and regulatory experience as well as business insights to the Azafaros team.
Leiden, The Netherlands, July 23th, 2018 – Azafaros, a biotech company established in Leiden in the Netherlands, focusing on the development of new therapies in the field of rare metabolic disorders, today announced the closing of a seed financing round. BioGeneration...